ReviewMedical devices (Auckland, N.Z.)2015
Brain delivery of small interfering ribonucleic acid and drugs through intranasal administration with nano-sized polymer micelles.
Review in Medical devices (Auckland, N.Z.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Intranasal administration in modulating depressive-like behavior and reconstructing treatment paradigms through neuroinflammation and neurotrophic pathways.Journal of nanobiotechnology · 2026Review
- Nucleic Acid-based Therapy in Effective Management of Rheumatoid Arthritis.Current pharmaceutical design · 2025Review
- Cell-Penetrating Peptides as Valuable Tools for Nose-to-Brain Delivery of Biological Drugs.Cells · 2023Review
- Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders.Acta pharmaceutica Sinica. B · 2023Review
- Olfactory Drug Aerosol Delivery with Acoustic Radiation.Biomedicines · 2022Article
- Systemic and brain delivery of antidiabetic peptides through nasal administration using cell-penetrating peptides.Frontiers in pharmacology · 2022Review
- Intranasal delivery: An attractive route for the administration of nucleic acid based therapeutics for CNS disorders.Frontiers in pharmacology · 2022Review
- Nose-to-brain delivery: exploring newer domains for glioblastoma multiforme management.Drug delivery and translational research · 2020Review
- Article
- Could the Olfactory System Be a Target for Homeopathic Remedies as Nanomedicines?Journal of alternative and complementary medicine (New York, N.Y.) · 2018Article
- Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting.Pharmaceutics · 2018Review
- The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders.Molecular psychiatry · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, the development of effective strategies for enhancing drug delivery to the brain has been a topic of great interest in both clinical and pharmaceutical fields. In this review, we summarize our studies evaluating nose-to-brain delivery of drugs and small interfering ribonucleic acids in combination with cell-penetrating peptide-modified polymer micelles. Our findings show that the use of polymer micelles with surface modification with Tat peptide in the intranasal administration enables the non-invasive delivery of therapeutic agents to the brain by increasing the transfer of the administered drug or small interfering ribonucleic acid to the central nervous system from the nasal cavity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.